Climb Bio (CLYM) Return on Capital Employed (2021 - 2026)

Climb Bio has reported Return on Capital Employed for 6 years, with the latest figure at 38.51% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1202.0% year-over-year to 38.51%; the trailing twelve-month figure through Mar 2026 stood at 38.51% (up 1202.0% YoY), and the FY2025 full-year result was 36.6%, up 1502.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 38.51%, up from 40.4% in the prior quarter.
• The five-year high for Return on Capital Employed was 18.55% in Q1 2024, with the low at 50.53% in Q1 2025.
• Historically, Return on Capital Employed has averaged 36.14% across 5 years, with a median of 37.03% in 2023.
• Annual changes were most pronounced in 2024 — Return on Capital Employed surged 2629 bps — and 2025, when it sank 3198 bps.
• Climb Bio's Return on Capital Employed stood at 34.24% in 2022, then dropped by 8 bps to 37.03% in 2023, then retreated by 3 bps to 38.19% in 2024, then retreated by 6 bps to 40.4% in 2025, then gained by 5 bps to 38.51% in 2026.
• The last three Return on Capital Employed figures came in at 38.51% (Q1 2026), 40.4% (Q4 2025), and 32.62% (Q3 2025), per Business Quant data.